New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:02 EDTLGNDLigand announces presentation of data from Phase 1 study
Ligand Pharmaceuticals announced that data from a Phase 1 study of the selective estrogen receptor modulator lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours; There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments; Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone; doses of 30 and 100 mg increased levels of T by more than 80%; Levels of luteinizing hormone and follicle-stimulating hormone were also elevated with single oral doses of 30 and 100 mg; Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days; T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
08:03 EDTLGNDGlaxoSmithKline receives FDA approval for sNDA for Promacta/Revolade
Ligand Pharmaceuticals Incorporated (LGND) announced that its partner GlaxoSmithKline (GSK) has received approval of a supplemental New Drug Application for the once-daily use of Promacta/Revolade in patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells and platelets.2 Eltrombopag, an oral thrombopoietin receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.
August 25, 2014
11:45 EDTLGNDLemelson says Ligand has 'lost favor with largest investors'
Subscribe for More Information
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Subscribe for More Information
August 14, 2014
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use